Valuation: Shivalik Rasayan Limited

Market Cap 3.49B 36.78M 32.22M 29.74M 27.54M 52.22M 53.1M 356M 139M 1.72B 138M 135M 5.96B P/E 2024
69.1x
P/E 2025 59.1x
Enterprise Value 4.26B 44.86M 39.3M 36.27M 33.59M 63.7M 64.77M 435M 169M 2.1B 168M 165M 7.27B EV / Sales 2024
3.49x
EV / Sales 2025 3.4x
Free-Float
40.79%
Yield 2024
0.09%
Yield 2025 0.08%
05-27 Shivalik Rasayan Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
05-27 Shivalik Rasayan Limited Announces Resignation of Sanjay Bansal as Non-Executive Director, Effective May 27, 2026 CI
05-27 Shivalik Rasayan Limited Recommends Final Dividend for the Financial Year 2025-26 CI
05-27 Shivalik Rasayan Ltd March-quarter consol net profit 45.3 million rupees RE
02-13 Shivalik Rasayan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-14 Shivalik Rasayan Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
25-09-29 Shivalik Rasayan Limited Approves the Re-Designation of Mr. Ashwani Kumar Sharma as a Non-Executive, Non-Independent Director CI
25-08-12 Shivalik Rasayan Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-30 Shivalik Rasayan Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
25-05-29 Shivalik Rasayan Limited announces Annual dividend, payable on October 27, 2025 CI
25-04-23 Medicamen Biotech Limited announced that it has received INR 535.6816 million in funding from Kim Ginnerup ApS, Shivalik Rasayan Limited, VERALOGIX HOLDINGS LTD and other investors CI
25-02-25 Medicamen Biotech Limited announced that it expects to receive INR 775.7875 million in funding from Kim Ginnerup ApS, Shivalik Rasayan Limited, VERALOGIX HOLDINGS LTD CI
24-10-04 Shivalik Rasayan Gets US FDA Nod for Pharmaceutical Ingredient Facility in Gujarat; Shares Rise 3% MT
1 day-5.00%
1 week-1.46%
Current month-6.14%
1 month-4.76%
3 months-7.70%
6 months-36.57%
Current year-37.53%
1 week 222.3
Extreme 222.3
245
1 month 206
Extreme 206
245
Current year 206
Extreme 206
371.3
1 year 206
Extreme 206
652.75
3 years 206
Extreme 206
890.05
5 years 206
Extreme 206
1,196.8
10 years 34.2
Extreme 34.2
1,196.8
Manager TitleAgeSince
Chief Executive Officer 64 2018-11-16
Director of Finance/CFO - 2001-10-31
Chief Tech/Sci/R&D Officer - 2024-01-10
Director TitleAgeSince
Chairman 61 2002-02-22
Director/Board Member 67 2003-07-17
Director/Board Member - 2018-11-12
Date Insider Type Main position Quantity % Market Cap.
24-06-30Don 21,500 0.1382%
24-06-25Sell 108,500 0.6973%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%-1.46%-58.56%-71.45% 38.64M
+0.42%+2.43%+13.28%+51.40% 57.78B
+0.11%-.--%-.--%-.--% 12.96B
+2.55%+3.81%+53.88%+201.03% 11.07B
-4.72%-9.70%+30.06%+68.97% 8.13B
-1.98%-0.60%-30.77%-13.46% 6.52B
-1.60%-0.64%-8.14%+81.49% 5.96B
-1.37%+5.61%-11.81%-10.80% 5.39B
+0.88%-0.12%+19.97%+26.42% 4.66B
-0.97%+3.52%-37.09%-31.20% 4.26B
Average -1.17%+2.15%-2.92%+30.24% 11.68B
Weighted average by Cap. -0.12%+2.21%+10.52%+52.10%

Financials

2024 2025
Net sales 2.72B 28.6M 25.05M 23.12M 21.41M 40.6M 41.29M 277M 108M 1.34B 107M 105M 4.64B 3.1B 32.6M 28.55M 26.36M 24.41M 46.28M 47.06M 316M 123M 1.53B 122M 120M 5.28B
Net income 127M 1.34M 1.17M 1.08M 1M 1.9M 1.93M 12.98M 5.04M 62.73M 5.03M 4.92M 217M 167M 1.76M 1.54M 1.42M 1.32M 2.5M 2.54M 17.04M 6.62M 82.35M 6.6M 6.46M 285M
Net Debt 482M 5.08M 4.45M 4.11M 3.8M 7.21M 7.33M 49.22M 19.13M 238M 19.07M 18.65M 823M 768M 8.08M 7.08M 6.54M 6.05M 11.48M 11.67M 78.33M 30.44M 379M 30.35M 29.69M 1.31B
Logo Shivalik Rasayan Limited
Shivalik Rasayan Limited is an India-based company. The Company’s segments are engaged in agrochemicals, active pharma ingredients (API), and pharma formulation. It is the producer of Malathion Technical and Dimethoate Technical. Malathion Technical is a non-systemic, wide spectrum organophosphorus (OP) based contact insecticide. Dimethoate Technical is used in preparation of formulations used in the control of a range of insects and mites. It also manufactures organophosphorus-based insecticides and chemicals. It has a diverse product range and product mix in order to serve consumer requirements. The APIs are being developed and manufactured in the niche area of oncology, ARVs, cardiovascular, metabolic disorders and immunology. It offers solutions from product selection to development to commercialization for a range of oncology and non-oncology products. The Company’s oncology products include Azacitidine, Busulfan, Bortezomib, and various others.
Employees
275
Date Price Change Volume
26-07-07 ₹222.30 -5.00% 1,533
26-07-06 ₹234.00 +1.96% 1,799
26-07-03 ₹229.50 -2.82% 946
26-07-02 ₹236.15 +1.72% 1,791
26-07-01 ₹232.15 -1.98% 2,707
  1. Stock Market
  2. Stocks
  3. SHIVALIK Stock